NEDD 8 pathway inhibition is effective in preclinical models of poorly differentiated , clinically aggressive colorectal cancer

Picco, Gabriele; Petti, Consalvo; Sassi, Francesco; Grillone, Katia; Migliardi, Giorgia; Rossi, Teresa; Isella, Claudio; Di Nicolantonio, Federica; Sarotto, Ivana; Sapino, Anna; Bardelli, Alberto; Trusolino, Livio; Bertotti, Andrea; Medico, Enzo. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 109 (2) pp: 1-12. DOI: 10.1093/jnci/djw209

[1]  K. Okuno,et al.  Clinicopathological and genetic differences between low‐grade and high‐grade colorectal mucinous adenocarcinomas , 2015, Cancer.

[2]  M. Linnebacher,et al.  Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype , 2015, PloS one.

[3]  Hong-Chiang Chang,et al.  MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma , 2015, Scientific Reports.

[4]  G. Mulligan,et al.  Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma , 2015, Clinical Cancer Research.

[5]  F. Wolenski,et al.  The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis , 2015, Cell Death Discovery.

[6]  R. Scharpf,et al.  The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer , 2015, Nature.

[7]  Jeffrey W. Clark,et al.  Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[8]  P. Chen,et al.  The novel protective role of P27 in MLN4924-treated gastric cancer cells , 2015, Cell Death and Disease.

[9]  J. Brown,et al.  Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents , 2015, Cell Death and Disease.

[10]  M. Maris,et al.  Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study , 2015, British journal of haematology.

[11]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[12]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[13]  M. Linnebacher,et al.  Establishment and characterization of cell lines from chromosomal instable colorectal cancer. , 2015, World journal of gastroenterology.

[14]  J. Maciejewski,et al.  The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine , 2014, Clinical Cancer Research.

[15]  A. Bardelli,et al.  Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.

[16]  N. I. Pospekhova,et al.  Epithelial-Mesenchymal Transition and Somatic Alteration in Colorectal Cancer with and without Peritoneal Carcinomatosis , 2014, BioMed research international.

[17]  T. Rikiyama,et al.  Molecular biomarkers for the detection of metastatic colorectal cancer cells. , 2014, World journal of gastroenterology.

[18]  E. Lightcap,et al.  Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways , 2014, Molecular Cancer Therapeutics.

[19]  D. Zecchin,et al.  BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors , 2013, Molecular Cancer Therapeutics.

[20]  A. Jazaeri,et al.  Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924 , 2013, Molecular Cancer Therapeutics.

[21]  Seung-Yong Jeong,et al.  Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy , 2013, British Journal of Cancer.

[22]  Peter G. Smith,et al.  Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Ostwald,et al.  Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas , 2012, PloS one.

[24]  R. Yantiss,et al.  Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. , 2012, American journal of clinical pathology.

[25]  C. Kunisaki,et al.  The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease , 2012, World Journal of Surgical Oncology.

[26]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[27]  Yi Sun,et al.  The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme , 2012, PloS one.

[28]  I. Nagtegaal,et al.  Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. , 2012, European journal of cancer.

[29]  Hirohito Yamaguchi,et al.  Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. , 2012, Cancer research.

[30]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[31]  F. Khuri,et al.  The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells , 2011, Molecular Cancer Therapeutics.

[32]  Lijun Jia,et al.  Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. , 2011, Neoplasia.

[33]  F. Cebrià,et al.  EGFR signaling regulates cell proliferation, differentiation and morphogenesis during planarian regeneration and homeostasis. , 2011, Developmental biology.

[34]  Thomas Hartmann,et al.  The cullin protein family , 2011, Genome Biology.

[35]  M. Ohh,et al.  NEDD8 pathways in cancer, Sine Quibus Non. , 2011, Cancer cell.

[36]  David B Jackson,et al.  EMT is the dominant program in human colon cancer , 2011, BMC Medical Genomics.

[37]  Anindya Dutta,et al.  NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. , 2010, Cancer research.

[38]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[39]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[40]  Peter G. Smith,et al.  Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer , 2009, Clinical Cancer Research.

[41]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[42]  D. Hedley,et al.  Cancer stem cells, hypoxia and metastasis. , 2009, Seminars in radiation oncology.

[43]  F. Caponigro,et al.  The ubiquitin–proteasome system as a molecular target in solid tumors: an update on bortezomib , 2009, OncoTargets and therapy.

[44]  M. Peter,et al.  Function and regulation of protein neddylation , 2008, EMBO reports.

[45]  Kou-Juey Wu,et al.  Direct regulation of TWIST by HIF-1α promotes metastasis , 2008, Nature Cell Biology.

[46]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  L. Schwartz,et al.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Michael Peyton,et al.  Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.

[50]  E. Yeh,et al.  Characterization of NEDD8, a Developmentally Down-regulated Ubiquitin-like Protein* , 1997, The Journal of Biological Chemistry.

[51]  Hua Li,et al.  Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. , 2012, Cancer research.

[52]  D. Lacombe,et al.  An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. , 2009, European journal of cancer.

[53]  Z. Hua Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .